Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

25 participants · First posted Feb 24, 2020

Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

20 participants · First posted Jul 1, 2026

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

27 participants · First posted Aug 29, 2025

second-generation anti-CALR CAR T-cell therapy (myeloproliferative neoplasms)

JAK2 inhibitors (myeloproliferative disease)

Anagrelide(Xagrid, Agrylin, Anagrelide Viatris (previously Anagrelide Mylan))

C₁₀H₇Cl₂N₃O · Rx

Ventyx Biosciences

United States

Wuhan Healthgen Biotechnology Corp.

Context Therapeutics

United States

Azacitidine-Ruxolitinib Combination Shows Promise for Advanced Myeloproliferative Neoplasms

Outcomes Remain Poor for Myeloproliferative Neoplasm Blast Phase Despite New Therapies

ACCC Initiative Enhances Care Standards for Myeloproliferative Neoplasms Across US Centers